ACY-6 Oral Administration of Acyline

• Status: Completed
• Trial end date: 2007-08-01
• Target enrollment: 0
• Participant gender: Male

Summary

In this study, we propose oral dosing of GIPET enhanced oral acyline (MER-104) to determine if this potentially useful compound is safe and effective at suppression of gonadotropins after oral dosing in man.

Hypothesis: A single dose of Acyline will suppress gonadotropins, and testosterone, estradiol and dihydrotestosterone (DHT) for 24 hours in man, and the magnitude and duration of the suppression will increase with increasing doses of Acyline.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Washington
• Collaborator: Merrion Pharmaceuticals, LLC
• Treatments: Acyline

Criteria

Inclusion Criteria:

• Males between 18-50 years of Age in good health

Exclusion Criteria:

• Men in poor health, significant chronic or acute medical illness, known history of alcohol, illicit drug or anabolic steroid abuse